Calliditas Therapeutics AB (publ) (CALTX.ST)
SEK 208.0
(0.87%)
SEK 208.0
(0.87%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -434.65 Million | -311.35 Million | -461.58 Million | -309.18 Million | -71.01 Million | -128.19 Million |
| Net Income | -466.18 Million | -421.94 Million | -524.45 Million | -379.72 Million | -28.01 Million | -132.48 Million |
| Depreciation & Amortization | 16.59 Million | 12.91 Million | 34.43 Million | 2.82 Million | 1.82 Million | 51 Thousand |
| Deferred income taxes | - | - | -65.67 Million | 7.62 Million | 776 Thousand | - |
| Stock-based compensation | 52.59 Million | 35.79 Million | 21.96 Million | 6.01 Million | 249 Thousand | - |
| Change in working capital | -79.74 Million | 88.42 Million | 5.47 Million | 54.08 Million | -45.9 Million | 4.24 Million |
| Other non-cash items | 207.6 Million | -26.53 Million | 66.67 Million | -4000.00 | 62 Thousand | 49 Thousand |
| Investing Cash Flow | -13.74 Million | -5.14 Million | -24.34 Million | -172.6 Million | -18.07 Million | - |
| Investments in PPE | -12.78 Million | -2.51 Million | -22.65 Million | - | -16.18 Million | - |
| Acquisitions | - | - | -47.02 Million | -172.6 Million | - | - |
| Investment purchases | -1.56 Million | -2.63 Million | -1.68 Million | -5000.00 | -1.88 Million | - |
| Sales/Maturities of investments | 602 Thousand | - | 71.36 Million | - | - | - |
| Other Investing Activities | 1000.00 | 1000.00 | -24.34 Million | -172.6 Million | -17.95 Million | - |
| Financing Cash Flow | 199.65 Million | 575.99 Million | 435.16 Million | 768.55 Million | 198.83 Million | 716.57 Million |
| Debt repayment | -211.78 Million | -9.61 Million | -5.57 Million | -3.97 Million | -1.65 Million | -470 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -236 Thousand | - | - | - | - |
| Common Stock Issuance | - | 236 Thousand | 324 Million | 891.38 Million | 210.31 Million | 768.64 Million |
| Other Financing Activities | -26.62 Million | 585.6 Million | 116.73 Million | -118.85 Million | -9.83 Million | -51.6 Million |
| Accounts receivables | -182.58 Million | -91.87 Million | -11.71 Million | 8.03 Million | -53.54 Million | 2.64 Million |
| Accounts payables | 119.62 Million | 183.05 Million | 18.13 Million | 46.05 Million | 7.64 Million | 1.6 Million |
| Inventory | -16.78 Million | -2.75 Million | -949 Thousand | - | 45.9 Million | - |
| Other working capital | -79.74 Million | 183.05 Million | 18.13 Million | 1.00 | -45.9 Million | 1.6 Million |
| Cash at beginning of period | 1.24 Billion | 955.5 Million | 996.3 Million | 753.54 Million | 656.17 Million | 57.35 Million |
| Cash at end of period | 973.73 Million | 1.24 Billion | 955.5 Million | 996.3 Million | 753.54 Million | 646.17 Million |
| Capital Expenditure | -12.78 Million | -2.51 Million | -22.65 Million | - | -16.18 Million | - |
| Effect of forex changes on cash | -26.61 Million | 34.09 Million | 9.96 Million | -44 Million | -2.38 Million | 442 Thousand |
| Net cash flow / Change in cash | -275.36 Million | 293.58 Million | -40.79 Million | 242.76 Million | 97.36 Million | 588.82 Million |
| Free Cash Flow | -447.44 Million | -313.86 Million | -484.24 Million | -309.18 Million | -87.19 Million | -128.19 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -47.47 Million | -203.82 Million | -466.18 Million | -18.36 Million | -159.57 Million | -75.17 Million |
| Depreciation & Amortization | - | - | 16.59 Million | 16.59 Million | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | 52.59 Million | 52.59 Million | - | - |
| Change in working capital | -32.4 Million | 13.62 Million | -79.74 Million | -28.12 Million | 60.16 Million | -49.56 Million |
| Other non-cash items | 72.84 Million | 16.25 Million | 207.6 Million | 69.33 Million | 36.88 Million | -38.29 Million |
| Investing Cash Flow | -102 Thousand | -3.85 Million | -13.74 Million | -2.35 Million | -7.41 Million | -1.06 Million |
| Investments in PPE | 7.04 Million | - | -12.78 Million | -12.78 Million | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | -1.56 Million | - | - | - |
| Sales/Maturities of investments | - | - | 602 Thousand | - | - | - |
| Other Investing Activities | -102 Thousand | -3.85 Million | 1000.00 | 11.39 Million | -7.41 Million | -1.06 Million |
| Financing Cash Flow | -4.04 Million | -5.46 Million | 199.65 Million | 208.52 Million | -2.88 Million | -3.01 Million |
| Debt repayment | -4.06 Million | -5.46 Million | -211.78 Million | -235.14 Million | -2.88 Million | -3.01 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 14 Thousand | - | - | - | - | - |
| Other Financing Activities | -4.06 Million | - | -26.62 Million | -26.62 Million | -2.88 Million | -3.01 Million |
| Accounts receivables | - | - | -182.58 Million | -182.58 Million | - | - |
| Accounts payables | - | - | 119.62 Million | - | - | - |
| Inventory | - | - | -16.78 Million | -16.78 Million | - | - |
| Other working capital | -32.4 Million | 13.62 Million | -79.74 Million | -28.12 Million | 60.16 Million | -49.56 Million |
| Cash at beginning of period | 810.31 Million | 973.73 Million | 1.24 Billion | 786.88 Million | 866.18 Million | 1.01 Billion |
| Cash at end of period | 797.27 Million | 810.31 Million | 973.73 Million | 973.73 Million | 786.88 Million | 866.18 Million |
| Capital Expenditure | 7.04 Million | - | -12.78 Million | -12.78 Million | - | - |
| Effect of forex changes on cash | -1.84 Million | 44.11 Million | -26.61 Million | -42.16 Million | -6.46 Million | 19.68 Million |
| Net cash flow / Change in cash | -13.03 Million | -163.41 Million | -275.36 Million | 186.85 Million | -79.29 Million | -147.41 Million |
| Free Cash Flow | - | -198.2 Million | -447.44 Million | 10.05 Million | -62.52 Million | -163.03 Million |
SCYT
600415
1440
ADVIKCA
SCNLF
ORCH